Literature DB >> 19373218

The endocannabinoid system: potential for reducing cardiometabolic risk.

Henry N Ginsberg1, Stephen C Woods.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19373218      PMCID： PMC2905146          DOI： 10.1038/oby.2009.107

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN： 1930-7381            Impact factor:   5.002


× No keyword cloud information.
  88 in total

Review 1.  Cannabinoid-based drugs as anti-inflammatory therapeutics.

Authors:  Thomas W Klein
Journal:  Nat Rev Immunol       Date:  2005-05       Impact factor: 53.106

Review 2.  Endocannabinoids and liver disease. IV. Endocannabinoid involvement in obesity and hepatic steatosis.

Authors:  George Kunos; Douglas Osei-Hyiaman
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-02-21       Impact factor: 4.052

Review 3.  Endocannabinoids, adipose tissue and lipid metabolism.

Authors:  C Pagano; M Rossato; R Vettor
Journal:  J Neuroendocrinol       Date:  2008-05       Impact factor: 3.627

Review 4.  Adiponectin--journey from an adipocyte secretory protein to biomarker of the metabolic syndrome.

Authors:  M E Trujillo; P E Scherer
Journal:  J Intern Med       Date:  2005-02       Impact factor: 8.989

5.  CB1 cannabinoid receptor-mediated modulation of food intake in mice.

Authors:  Jenny L Wiley; James J Burston; Darnica C Leggett; Olga O Alekseeva; Raj K Razdan; Anu Mahadevan; Billy R Martin
Journal:  Br J Pharmacol       Date:  2005-06       Impact factor: 8.739

6.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Authors:  Luc F Van Gaal; Aila M Rissanen; André J Scheen; Olivier Ziegler; Stephan Rössner
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

7.  Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity.

Authors:  Douglas Osei-Hyiaman; Michael DePetrillo; Pál Pacher; Jie Liu; Svetlana Radaeva; Sándor Bátkai; Judith Harvey-White; Ken Mackie; László Offertáler; Lei Wang; George Kunos
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

Review 8.  Rimonabant--a selective CB1 antagonist.

Authors:  Steven Thomas Boyd; Brad Allen Fremming
Journal:  Ann Pharmacother       Date:  2005-03-08       Impact factor: 3.154

9.  Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.

Authors:  Steven E Nissen; Stephen J Nicholls; Kathy Wolski; Josep Rodés-Cabau; Christopher P Cannon; John E Deanfield; Jean-Pierre Després; John J P Kastelein; Steven R Steinhubl; Samir Kapadia; Muhammad Yasin; Witold Ruzyllo; Christophe Gaudin; Bernard Job; Bo Hu; Deepak L Bhatt; A Michael Lincoff; E Murat Tuzcu
Journal:  JAMA       Date:  2008-04-01       Impact factor: 56.272

10.  The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system.

Authors:  Blerina Kola; Imre Farkas; Mirjam Christ-Crain; Gábor Wittmann; Francesca Lolli; Faisal Amin; Judith Harvey-White; Zsolt Liposits; George Kunos; Ashley B Grossman; Csaba Fekete; Márta Korbonits
Journal:  PLoS One       Date:  2008-03-12       Impact factor: 3.240
View more
  4 in total

1.  Homology modelling of CB1 receptor and selection of potential inhibitor against Obesity.

Authors:  Mahesh Shrinivasan; Sinosh Skariyachan; Vaka Aparna; Vinod Rama Kolte
Journal:  Bioinformation       Date:  2012-06-16

2.  High-fat diet-induced insulin resistance does not increase plasma anandamide levels or potentiate anandamide insulinotropic effect in isolated canine islets.

Authors:  Orison O Woolcott; Joyce M Richey; Morvarid Kabir; Robert H Chow; Malini S Iyer; Erlinda L Kirkman; Darko Stefanovski; Maya Lottati; Stella P Kim; L Nicole Harrison; Viorica Ionut; Dan Zheng; Isabel R Hsu; Karyn J Catalano; Jenny D Chiu; Heather Bradshaw; Qiang Wu; Cathryn M Kolka; Richard N Bergman
Journal:  PLoS One       Date:  2015-04-09       Impact factor: 3.240

3.  Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity.

Authors:  Lirit N Franks; Benjamin M Ford; Paul L Prather
Journal:  Front Pharmacol       Date:  2016-12-22       Impact factor: 5.810

Review 4.  Cannabis sativa as a Treatment for Obesity: From Anti-Inflammatory Indirect Support to a Promising Metabolic Re-Establishment Target.

Authors:  Eulla Keimili Fernandes Ferreira Cavalheiro; Ana Beatriz Costa; Daniéle Hendler Salla; Mariella Reinol da Silva; Talita Farias Mendes; Larissa Espindola da Silva; Cristini da Rosa Turatti; Rafael Mariano de Bitencourt; Gislaine Tezza Rezin
Journal:  Cannabis Cannabinoid Res       Date:  2021-07-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.